FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., announced its in...
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib) Once-daily Jakafi XR was shown to provide consisten...
Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for i...
InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the pr...
Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is sea...
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administra...
TrialClinIQ, an AI-powered clinical trial recruitment platform based in Houston, Texas advancing health equity, announced a $150K pre-seed investment fro...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its pivotal Phase 3 cl...
Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordin...
Santhera Pharmaceuticals (SIX: SANN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA...
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clini...
Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire's novel off-the-shelf T cell receptor (TCR) bispecific therapy as ...
© 2026 Biopharma Boardroom. All Rights Reserved.
